ZA202105654B - Method of producing a binder-toxin fusion protein in a plant cell or a whole plant - Google Patents
Method of producing a binder-toxin fusion protein in a plant cell or a whole plantInfo
- Publication number
- ZA202105654B ZA202105654B ZA2021/05654A ZA202105654A ZA202105654B ZA 202105654 B ZA202105654 B ZA 202105654B ZA 2021/05654 A ZA2021/05654 A ZA 2021/05654A ZA 202105654 A ZA202105654 A ZA 202105654A ZA 202105654 B ZA202105654 B ZA 202105654B
- Authority
- ZA
- South Africa
- Prior art keywords
- binder
- producing
- fusion protein
- plant
- toxin fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19157839 | 2019-02-18 | ||
| PCT/EP2020/054263 WO2020169620A1 (en) | 2019-02-18 | 2020-02-18 | Method of producing a binder-toxin fusion protein in a plant cell or a whole plant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202105654B true ZA202105654B (en) | 2023-04-26 |
Family
ID=65717705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/05654A ZA202105654B (en) | 2019-02-18 | 2021-08-05 | Method of producing a binder-toxin fusion protein in a plant cell or a whole plant |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220090113A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3927831B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7150999B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102398485B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115925972A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021016348A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3128793C (cg-RX-API-DMAC7.html) |
| ES (1) | ES3055338T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL285719B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020169620A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202105654B (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102398485B1 (ko) * | 2019-02-18 | 2022-05-16 | 에이티비 테라퓨틱스 | 식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법 |
| US20230203108A1 (en) * | 2020-05-28 | 2023-06-29 | Chugai Seiyaku Kabushiki Kaisha | Improved granzyme b variant |
| WO2022038152A1 (en) | 2020-08-17 | 2022-02-24 | Atb Therapeutics | Recombinant immunotoxin comprising a ribotoxin or rnase |
| EP4328243A4 (en) * | 2021-04-20 | 2025-05-21 | Korea University Research and Business Foundation | Asymmetric antibody with improved cytotoxicity against cancer cell |
| CN117440971A (zh) * | 2021-04-20 | 2024-01-23 | 高丽大学校产学协力团 | 具有提高的癌细胞杀灭功效的非对称抗体 |
| WO2023156634A1 (en) | 2022-02-17 | 2023-08-24 | Atb Therapeutics | Recombinant immunotoxin comprising a ribosome inactivating protein |
| CN114605556B (zh) * | 2022-03-10 | 2023-04-14 | 南开大学 | 一种增强植物根系募集功能细菌的融合蛋白及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6140075A (en) | 1994-07-25 | 2000-10-31 | Monsanto Company | Method for producing antibodies and protein toxins in plant cells |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| CA2454048C (en) * | 2001-07-17 | 2011-05-03 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| ATE306810T1 (de) | 2002-03-05 | 2005-11-15 | Artemis Pharmaceuticals Gmbh | Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse |
| JP2006507800A (ja) | 2002-06-07 | 2006-03-09 | ラージ・スケール・バイオロジー・コーポレイション | 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム |
| AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| US20090148904A1 (en) * | 2007-11-13 | 2009-06-11 | Mayfield Stephen P | Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
| EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| US9586996B2 (en) | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| PH12012502433A1 (en) | 2010-06-09 | 2013-02-11 | Du Pont | Regulatory sequences for modulating transgene expression in plants |
| CN111363047A (zh) | 2013-03-12 | 2020-07-03 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| WO2016187585A1 (en) * | 2015-05-20 | 2016-11-24 | Viventia Bio Inc. | Deimmunized linker and methods of use |
| CN105753986B (zh) * | 2016-04-24 | 2019-12-10 | 赵磊 | 一类抗cd20靶向抗体及用途 |
| KR102398485B1 (ko) * | 2019-02-18 | 2022-05-16 | 에이티비 테라퓨틱스 | 식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법 |
-
2020
- 2020-02-18 KR KR1020217027132A patent/KR102398485B1/ko active Active
- 2020-02-18 CN CN202210858173.1A patent/CN115925972A/zh active Pending
- 2020-02-18 JP JP2021548219A patent/JP7150999B2/ja active Active
- 2020-02-18 CA CA3128793A patent/CA3128793C/en active Active
- 2020-02-18 EP EP20704343.1A patent/EP3927831B1/en active Active
- 2020-02-18 US US17/431,374 patent/US20220090113A1/en active Pending
- 2020-02-18 WO PCT/EP2020/054263 patent/WO2020169620A1/en not_active Ceased
- 2020-02-18 IL IL285719A patent/IL285719B/en unknown
- 2020-02-18 BR BR112021016348A patent/BR112021016348A2/pt unknown
- 2020-02-18 CN CN202080029119.5A patent/CN113728107B/zh active Active
- 2020-02-18 ES ES20704343T patent/ES3055338T3/es active Active
- 2020-02-18 EP EP25209159.0A patent/EP4733324A3/en active Pending
-
2021
- 2021-08-05 ZA ZA2021/05654A patent/ZA202105654B/en unknown
-
2022
- 2022-07-27 JP JP2022119504A patent/JP7728587B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022518614A (ja) | 2022-03-15 |
| JP2022176933A (ja) | 2022-11-30 |
| IL285719A (en) | 2021-10-31 |
| CN113728107B (zh) | 2022-06-24 |
| IL285719B (en) | 2022-07-01 |
| CA3128793A1 (en) | 2020-08-27 |
| ES3055338T3 (en) | 2026-02-11 |
| BR112021016348A2 (pt) | 2021-11-23 |
| EP4733324A3 (en) | 2026-06-24 |
| JP7728587B2 (ja) | 2025-08-25 |
| KR20210120051A (ko) | 2021-10-06 |
| CN115925972A (zh) | 2023-04-07 |
| EP3927831A1 (en) | 2021-12-29 |
| WO2020169620A1 (en) | 2020-08-27 |
| US20220090113A1 (en) | 2022-03-24 |
| EP3927831C0 (en) | 2025-11-12 |
| EP3927831B1 (en) | 2025-11-12 |
| KR102398485B1 (ko) | 2022-05-16 |
| JP7150999B2 (ja) | 2022-10-11 |
| EP4733324A2 (en) | 2026-04-29 |
| CN113728107A (zh) | 2021-11-30 |
| CA3128793C (en) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276597A (en) | A method for producing a low antigenic cell | |
| IL285719A (en) | Method of producing a binder-toxin fusion protein in a plant cell or a whole plant | |
| IL280387A (en) | A method for producing cells derived from dental pulp | |
| SG11202005433SA (en) | Scaffolding material for stem cell cultures and stem cell culture method using same | |
| HUP1800376A2 (hu) | Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer | |
| EP3587559A4 (en) | MANUFACTURING METHOD FOR ARTIFICIAL PLURIPOTENT STEM CELLS | |
| IL287318A (en) | Materials and methods for the production of proteins | |
| IL277467A (en) | A method for producing natural killer cells | |
| PT3835415T (pt) | Método para produção de células positivas para cd3 | |
| PL3999316T3 (pl) | Sposób i układ do wytwarzania trójwymiarowej porowatej struktury | |
| EP3950711A4 (en) | CELL CONSTRUCT AND METHODS OF PRODUCTION | |
| EP3279311A4 (en) | Artificial skin culture container and method for producing artificial skin using same | |
| PT3722504T (pt) | Material de enchimento de superfícies de relva artificial e processo para o seu fabrico | |
| EP4410965A4 (en) | T LYMPHOCYTE PRODUCTION PROCESS | |
| ZA202005741B (en) | Methods for improving cell viability in a production bioreactor | |
| EP3993010A4 (en) | LAYER BODY AND METHOD FOR PRODUCING A LAYER BODY | |
| EP3778902A4 (en) | Cell production method | |
| SG11202101902QA (en) | Biomaterial comprising adipose-derived stem cells and gelatin and method for producing the same | |
| EP3770249A4 (en) | METHOD OF THREE-DIMENSIONAL CULTIVATION OF PLURIPOTENT STEM CELLS | |
| EP3903991A4 (en) | THREE-DIMENSIONAL LAMINATION METHOD AND OBJECT HAVING A THREE-DIMENSIONAL SHAPE | |
| SG11202011845XA (en) | Production method for culture supernatant preparation | |
| HUE058887T2 (hu) | Háromfókuszú szemészeti mûlencse és eljárás annak elõállítására | |
| EP3254240A4 (en) | System and method for using artificial intelligence in making decisions | |
| SG10201806694VA (en) | Solar cell and manufacturing method therefor | |
| NO20191481A1 (en) | Energy production and storage system and method |